Ensuring Optimal Patient Outcomes in the Treatment and Management of Atopic Dermatitis in the Infant and Pediatric Population
Saturday, June 20, 2020
9:00 AM – 11:00 AM (Pacific Time)
12:00 AM Eastern; 11:00 AM Central; 10:00 AM Mountain; 09:00 AM Pacific
- 2.0 CME CREDITS
- Virtual reality animations
- Online personalized posters
Elaine Siegfried, MD
Director of Pediatric Dermatology
SSM Health Cardinal Glennon Children’s Hospital
Professor of Pediatrics and Dermatology
St. Louis University School of Medicine
St. Louis, MO
Marcia Hogeling, MD
Director, Pediatric Dermatology
Assistant Clinical Professor
Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
- Describe the impact of AD on physical, social, emotional, and mental aspects of patients’ lives throughout their lifespan
- Discuss best practices for achieving a timely and accurate diagnosis of AD in patients of all ages in order to initiate appropriate treatment
- Review the mechanisms of action and clinical profiles of current and emerging treatments for AD in infants, pediatric, adolescent, and adult patients
This activity is intended for US-based general pediatricians, internal medicine, and family physicians who are involved in the care and treatment of patients with AD.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 creditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis. Credits: 2.0 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at firstname.lastname@example.org
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.